The second China Pharmaceutical Innovation and Investment Conference opened

Source: on the morning of October 29, 2017, the second China Pharmaceutical Innovation and Investment Conference (hereinafter referred to as the conference) was held in Suzhou Industrial Park Join the sponsor and support unit The conference was jointly sponsored by China pharmaceutical innovation promotion association, China Securities Association, China Medical Device Industry Association, and Hong Kong stock exchange The conference was jointly sponsored by the implementation and Management Office of major science and technology projects of "major new drug creation", the research center of medical and health science and technology development of the national health and Family Planning Commission, the South Institute of pharmaceutical economics of the State Food and drug administration, and the Chinese medical department College, Chinese Academy of traditional Chinese medicine, science and technology promotion and Development Bureau of Chinese Academy of Sciences, Suzhou Industrial Park, national medical device industry technology innovation service alliance; Canadian business Commissioner Service Agency, British Columbia government of Canada, American Cancer Research Foundation, Japan Pharmaceutical Industry Association, JPMorgan Chase; Taiwan biotechnology and medical Industry Policy Association; foreign investment in China The pharmaceutical research and development industry committee of Enterprise Association and other well-known innovation, investment and financing institutions at home and abroad give strong support Nature, the world's top academic journal, as the first professional media, made professional reports on the conference In addition, it also invited the pharmaceutical economic news, health news, China Pharmaceutical News, China Securities News, Xinhua news agency economic reference news and national financial weekly, 21st century economic report, first financial daily, securities times, financial times and other authoritative medical and financial media to cover the whole process of the conference Ding liming, chairman of China Pharmaceutical Innovation Promotion Association (hereinafter referred to as "China pharmaceutical promotion association") and song Ruilin, executive chairman of China pharmaceutical promotion association, chairman of Beida Pharmaceutical Co., Ltd in 2016-2017 and executive chairman of China pharmaceutical promotion association, chairman of the organizing committee, presided over the stage of speech by the organizers and leaders of the conference From left to right: Ding Lieming, President of China Pharmaceutical Association for the year 2016-2017 and chairman of Beida Pharmaceutical Co., Ltd., Song Ruilin, executive president of China Pharmaceutical Association, sun Xianze, deputy director of State Food and drug administration, and Zeng Yixin, vice president of state health and Family Planning Commission delivered speeches Sun Xianze, deputy director general, pointed out that the 19th National Congress of the Communist Party of China marked that China has entered a new era, and the convening of the second congress is of great significance In the new era, the main goal of China's medical industry and regulatory departments is to meet the needs of the people for good drugs and new drugs The State Food and Drug Administration will take the "opinions on deepening the reform of review and approval system and encouraging the innovation of pharmaceutical and medical devices" as the basic program of the reform of pharmaceutical and medical devices, actively formulate a series of supporting policies, regulations and guidelines, actively promote and improve the solution of bottleneck problems in clinical trials, accelerate the review of listed drugs, and strengthen the whole life of pharmaceutical and medical devices In order to promote the development of drug innovation and generic drugs, we should manage the life cycle, enhance the technical support, improve the technical evaluation system and strengthen the organization and implementation Sun Xianze, deputy director of the State Food and drug administration, delivered a speech Deputy director of Zeng Yi Xin pointed out that the Party Central Committee with Comrade Xi Jinping as the core attached great importance to the work of health, health and scientific and technological innovation, and placed the priority on the development of people's health in the strategic position and placed scientific and technological innovation at the core of the overall development of the country Since 2008, the national health and Family Planning Commission has taken the lead in organizing the implementation of the national major science and technology special project of "major new drug creation", achieved significant stage results, broke through a number of bottleneck key technologies, such as antibody scale fermentation preparation and R & D technology platform construction, significantly improved drug innovation and internationalization capabilities, and effectively promoted the supply side reform and medicine industry Industrial innovation and development have played an important role in ensuring and improving people's livelihood, promoting industrial development, supporting medical reform and responding to emergencies At the same time, director Zeng also pointed out that the original innovation ability of China's pharmaceutical industry is still weak, the real original innovation, the "heavy bomb" drugs with international influence are not many, and the lack of clinical research ability is still the short board restricting China's pharmaceutical innovation Therefore, we should resolutely implement the spirit of the 19th National Congress of the Communist Party of China, closely focus on the implementation of the healthy China strategy, accelerate the deployment and implementation of the key tasks of the 13th five year plan, strengthen the capacity-building of clinical trials and clinical research, promote the transfer and transformation of achievements, and promote the improvement of the policy environment for pharmaceutical innovation from encouraging R & D application, centralized procurement and inclusion in the medical insurance catalog, and improve the pharmaceutical industry Support policies for pharmaceutical innovation in price negotiation, centralized procurement, medical insurance payment and other links will enable the masses to enjoy the achievements of scientific and technological innovation as soon as possible Zeng Yixin, deputy director of the national health and Family Planning Commission, addressed Ge Weiping, vice president of China Securities Association, Jiang Feng, executive vice president of China Medical Device Industry Association, and Xu Huimin, member of the Standing Committee of Suzhou Municipal Committee of Jiangsu Province and Secretary of the Party Working Committee of Suzhou Industrial Park, on behalf of the organizers, to wish the conference a success From left to right: Ge Weiping, vice president of China Securities Industry Association; Jiang Feng, executive vice president of China Medical Device Industry Association; Xu Huimin, member of the Standing Committee of Suzhou Municipal Committee and Secretary of the Party Working Committee of Suzhou Industrial Park, Jiangsu Province, promotes greater China and Sino US pharmaceutical innovation cooperation In order to strengthen the exchanges and cooperation in the field of Biomedical Innovation between the two sides of the Taiwan Strait, promote the sharing and co construction of new drug research and development, clinical trials, industrial development, policy supervision and other aspects, at the conference, song Ruilin, executive chairman of China pharmaceutical promotion association, Qian Zongliang, executive director of Taiwan biotechnology and medical industry promotion association, Lu Yulin, honorary chairman of Hong Kong Biotechnology Association, and Macao International China Wang Yitao, President of the pharmaceutical quality research association, jointly signed an agreement on innovation and cooperation of biomedicine between the two sides In order to carry out exchanges and cooperation in scientific research, clinical practice, industry and policy, the China Council for the promotion of drugs and the American Cancer Research Foundation will jointly build a "Sino US cooperation platform for cancer medicine innovation" to tackle cancer as a breakthrough point, jointly promote global medicine innovation and make due contributions to human health At the conference, Ding liming, President of China Association for the promotion of drugs 2016-2017 and Joseph franlin, President of American Cancer Research Foundation signed a memorandum of cooperation between the two sides From left to right: Lu Yulin, honorary chairman of Hong Kong Biotechnology Association, song Ruilin, executive chairman of China pharmaceutical promotion association, Qian Zongliang, executive director of Taiwan biotechnology and medical industry promotion association, and Wang Yitao, President of Macao International Association for quality research of traditional Chinese medicine signed the cooperation agreement on Biomedical Innovation in four places across the Taiwan Strait Ding liming, President of China Association for the promotion of drugs 2016-2017 and Joseph franlin, President of American Cancer Research Foundation signed a memorandum of cooperation The signing of the two cooperation agreements will play an important role in promoting the in-depth cooperation in pharmaceutical innovation between the Greater China region and China and the United States It also shows that the China pharmaceutical promotion association has made great efforts in promoting regional and international cooperation in pharmaceutical innovation and has been highly recognized by relevant organizations In order to promote the enthusiasm of capital to participate in pharmaceutical innovation, the conference focused on and discussed such important topics as global pharmaceutical investment trend analysis and international pharmaceutical research and clinical research Tian Yuan, vice chairman of the Executive Committee of the conference, vice chairman of the innovation and investment special committee of China pharmaceutical promotion association and founder partner of Shenzhen Qianhai Yuanming Asset Management Co., Ltd., presided over the report and Discussion on the global pharmaceutical investment trend analysis stage Tian Yuan, vice chairman of the Executive Committee of the Congress and founding partner of Shenzhen Qianhai Yuanming Asset Management Co., Ltd., presided over the keynote speech of "global economy and central bank policy" by Jacob A Frenkel, chairman of JPMorgan international Jacob A According to Frenkel's analysis of the current global economic development, the economy of the United States, Japan and Europe has recovered, with a growth rate of about 1% - 2%; however, the global economic center of gravity has become more and more inclined to developing countries The largest economic center is Asia, especially China and India, which are the main engines of economic growth in the world China's economic share now accounts for 18% of the global total 。 China is also a very important part of Global trade The annual export of the United States to China has increased from 7% in 2000 to 24.4% now, and the trade of the European Union to China has also increased from 5% to 25% Jacob A Frenkel also focuses on the analysis of the current global monetary policy He believes that the real shift of monetary policy will depend on whether the unemployment rate is reduced, whether the inflation rate has reached a high point, and whether he is ready to achieve an interest rate level of economic normalization by raising the economic leverage of interest rate Jacob A Frenkel, chairman of JPMorgan international, made a report Xu Zhengyu, managing director of Hong Kong stock exchange, made a keynote speech on "new economy, new finance and new medicine" Xu Zhengyu, the general manager of the board of directors, introduced the trading trend of Hong Kong stock exchange, as the asset management center of mainland investors for asset allocation abroad, after interconnection with the mainland capital market, analyzed the important role of the capital market in promoting the development of the medical industry, and looked forward to the development trend of the Chinese medical industry HKEx hopes to attract more medical industry companies to come to Hong Kong for listing through the establishment of innovation board, create a higher value chain of medical industry, let investors and researchers gather in Hong Kong, so as to play the role of HKEx in leading social capital to participate in medical innovation and promote the development of real economy Xu Zhengyu, managing director of the Hong Kong stock exchange, makes a report Gu Hongdi, chairman of JPMorgan Asia Pacific Investment Bank, Zhong Chuangxin, senior vice president of listing and issuance service of Hong Kong stock exchange market development section, Du Ying, chairman and chief executive officer of zaiding pharmaceutical, Li Zhenfu, founder, chairman and chief executive officer of Defu capital, Yin Yanwu, vice president of galaxy Securities and chairman of Galaxy Jinhui asset management company, and other representatives of investment and pharmaceutical innovative enterprises A heated discussion and dialogue were held on the trend of global pharmaceutical investment   From left to right: Tian Yuan, vice chairman of the Executive Committee of the conference, founding partner of Shenzhen Qianhai Yuanming Asset Management Co., Ltd., Gu Hongdi, chairman of JPMorgan Asia Pacific Investment Bank, Zhong Chuangxin, senior vice president of listing and issuance service of Hong Kong stock exchange market development section, Du Ying, chairman and CEO of zaiding pharmaceutical, Li Yuan, founder and chairman and CEO of Defu capital Zhenfu, vice president of Galaxy Securities and chairman of Galaxy Jinhui asset management company, Yin Yanwu, vice chairman of the Executive Committee of the Organizing Committee of the conference, chairman of the special committee for drug research and development of China pharmaceutical promotion association and chairman of Beijing jiakesi new drug research and Development Co., Ltd., Wang Yinxiang, presided over the report and Discussion on the international drug research and development and clinical research stage Wang Yinxiang, vice chairman of the Executive Committee of the Organizing Committee of the conference and chairman of Beijing jiakesi new drug research and Development Co., Ltd., presided over Mary Lynne Hedley, co-founder, President and chief operating officer of tesaro, and delivered a keynote speech "promoting therapeutic discovery and development through decentralized innovation" In the past six years, tesaro has explored and managed a strong external partnership, created a decentralized innovative drug development process, accelerated the expansion of the company's research product portfolio, achieved fruitful results, and challenged the traditional drug discovery and development model T